-sensitive fluorescent probes within RHT terminals were used to examine GABA B -receptor modulation of RHT transmission. Baclofen inhibited evoked excitatory postsynaptic currents (EPSCs) in a concentration-dependent manner equally during the day and night. Blockers of N-, P/Q-, T-, and R-type voltagedependent Ca 2ϩ channels, but not L-type, reduced the EPSC amplitude by 66, 36, 32, and 18% of control, respectively. Joint application of multiple Ca 2ϩ channel blockers inhibited the EPSCs less than that predicted, consistent with a model in which multiple Ca 2ϩ channels overlap in the regulation of transmitter release. Presynaptic inhibition of EPSCs by baclofen was occluded by -conotoxin GVIA (Յ72%), mibefradil (Յ52%), and -agatoxin TK (Յ15%), but not by SNX-482 or nimodipine. Baclofen reduced both evoked presynaptic Ca 2ϩ influx and resting Ca 2ϩ concentration in RHT terminals. Tertiapin did not alter the evoked EPSC and baclofen-induced inhibition, indicating that baclofen does not inhibit glutamate release by activation of Kir3 channels. Neither Ba 2ϩ nor high extracellular K ϩ modified the baclofen-induced inhibition. 4-Aminopyridine (4-AP) significantly increased the EPSC amplitude and the charge transfer, and dramatically reduced the baclofen effect. These data indicate that baclofen inhibits glutamate release from RHT terminals by blocking N-, T-, and P/Q-type Ca 2ϩ channels, and possibly by activation of 4-AP-sensitive K ϩ channels, but not by inhibition of R-and L-type Ca 2ϩ channels or by Kir3 channel activation.
I N T R O D U C T I O N
Suprachiasmatic nucleus (SCN) neurons of mammals contain a biological clock that synchronizes physiological processes with changing environmental conditions. To maintain proper temporal coupling between the circadian clock and the environment, neural systems have evolved to sense changing conditions and communicate that information to the clock. The daily change in light intensity (day/night) is the most important of these environmental signals. The SCN receives light intensity information by the retinohypothalamic tract (RHT), a direct glutamatergic projection from retinal ganglion cells (RGCs) to the SCN (Berson et al. 2002; Card and Moore 1991; Castel et al. 1993; Liou et al. 1986) Light's effect on circadian clock timing can be modified by neurotransmitters activating presynaptic receptors, thereby reducing glutamate release from RHT terminals. For example, activation of 5-HT 1B receptors reduces c-fos expression and the magnitude of light-induced phase shifts (Pickard et al. 1996 (Pickard et al. , 1999 . Similarly, activation of ␥-aminobutyric acid type B (GABA B ) receptors inhibits light-induced phase advances and phase delays (Colwell et al. 1993; Gillespie et al. 1997; Ralph and Menaker 1989) . Baclofen, a GABA B agonist, reduces the light-induced c-fos expression in the SCN that is often used as a physiologic measure of the activation of SCN neurons by light stimulation (Colwell et al. 1993; Gillespie et al. 1997; Pickard et al. 1996) . Thus GABA B receptors as well as 5-HT 1B receptors "act to prevent photic information from reaching the SCN" (Colwell et al. 1993; Pickard et al. 1996) . In hypothalamic slices baclofen reduces the amplitude of excitatory postsynaptic currents (EPSCs) evoked by optic nerve stimulation without altering the intrinsic activity of postsynaptic glutamate receptors (Jiang et al. 1995) . GABA B -receptor activation also reduces the frequency but does not alter the distribution of miniature EPSC amplitudes in SCN (Jiang et al. 1995) . Further, the GABA B antagonist phaclofen potentates the field potential induced by optic nerve stimulation, consistent with a tonic GABA B -receptor-mediated inhibition (Gannon et al. 1995) . Some of the RGCs that possess G-protein-coupled GABA B receptors may contribute axons to the RHT (Chen et al. 2004; Slaughter 1995) . These data are consistent with the hypothesis that activation of presynaptic GABA B receptors inhibits glutamate release from RHT terminals (Gannon et al. 1995; Jiang et al. 1995) .
Currently, the specific mechanism(s) by which GABA B receptors regulate neurotransmitter release at RHT terminals is not known. In the hippocampus, GABA B -receptor activation inhibits voltage-dependent Ca 2ϩ channels and activates K ϩ channels through a G(i/o)-type G-protein-mediated pathways (Andrade et al. 1986; Sodickson and Bean 1996) . The GABA Breceptor-mediated effect is attenuated by pertussis toxin uncoupling the G(i/o)-protein from the GABA B receptor. Loading G-protein beta-gamma subunits (G␤␥) into the calyceal nerve terminal partially occluded the inhibitory effect of baclofen on presynaptic Ca 2ϩ currents (Kajikawa et al. 2001 ). G␤␥ directly inhibits Ca 2ϩ channels, putting them into a "reluctant" state (Bertram et al. 2003; Zamponi and Snutch 1998) . Activation of GABA B receptors suppresses GABA release from the terminals of cultured SCN neurons through a G-protein-mediated inhibition of N-and P/Q-type Ca 2ϩ channels (Chen and Van den Pol 1998) . Also baclofen-induced inhibition of N-type Ca 2ϩ channels was found in axons of neonatal rat optic nerve (Sun and Chiu 1999) . In addition, baclofen activates fast inactivating A-type K ϩ channels and Ca 2ϩ -activated K ϩ channels (SK channels) (Bettler et al. 2004; Saint et al. 1990 ). We performed experiments to test the hypothesis that activation of presynaptic GABA B receptors acts to decrease evoked glutamate release from RHT terminals by inhibiting voltage-dependent Ca 2ϩ channels or by activating K ϩ channels.
M E T H O D S

Preparation of SCN brain slices
Male Sprague-Dawley rats (4 -6 wk old) were housed in an environmental chamber (Percival Scientific, Perry, IA) maintained at 20 -21°C on a 12 h light/12 h dark schedule. During the lights-on phase, rats were deeply anesthetized with halothane, their brains removed and submerged in an ice-cold Krebs solution consisting of (in mM): NaCl 126, KCl 2.5, NaH 2 PO 4 1.2, MgCl 2 4.0, CaCl 2 0.5, glucose 11, and NaHCO 3 26, saturated with 95% O 2 -5% CO 2 (301) (302) (303) . Coronal 250-to 300-m-thick slices of the hypothalamus containing the SCN were cut with a vibrating-blade microtome (Leica VT 1000 S, Nussloch, Germany). The Institutional Animal Care and Use Committee of OHSU approved all experimental procedures involving animals and all efforts were made to minimize pain and the number of animals used.
Whole cell patch-clamp recording
Recordings were made at 28 -30°C using the whole cell patchclamp technique from 1 to 8 h after slicing (Fig. 1A) . The recording solution was identical to the slicing solution, but contained (in mM): NaCl 130, NaHCO 3 22, CaCl 2 2.4, and MgCl 2 1.2 (pH 7.3-7.4, 300 -305 mOsm). Microelectrodes with resistances of 7-9 M⍀ were pulled from borosilicate glass (World Precision Instruments, Sarasota, FL) and filled with a solution containing (in mM): CsCH 3 O 3 S 105, CsCl 20, CaCl 2 1, HEPES 10, EGTA 11, CsOH 25, ATP 3, GTP 0.3, and QX-314 5. QX-314 was included in the patch pipette solution to block voltage-activated Na ϩ channels and K ϩ channels. Cs ϩ was used to block K ϩ channels including GABA B -activated K ϩ channels (Jiang et al. 1995) . To prevent activation of GABA A receptors, by GABA released from SCN GABAergic neurons after RHT stimulation, picrotoxin 50 M was added to the external solution. Individual SCN neurons were visualized with infrared illumination and differential interference contrast optics using a Leica DMLFS microscope with video camera and display (Sony). On-line data collection and analysis were performed using an EPC-7 patch-clamp amplifier (HEKA Electronik, Lambrecht, Germany), a Macintosh G3 computer, and Pulse and PulseFit (HEKA). The records were filtered at 3 kHz and digitized at 10 kHz.
To allow equilibration between the pipette solution and the cell cytoplasm contents, whole cell patch-clamp recording usually started 10 to 25 min after rupturing the cell membrane. During this time there was a rundown of the EPSC amplitude, which reached a plateau then remained stable for the next 1-1.5 h. Series resistance was typically 17-63 M⍀ (mean 33.3 Ϯ 0.7 M⍀, n ϭ 148) and was monitored by applying a small voltage step (1 mV, 5 ms) before optic chiasm stimulation. SCN neurons were voltage clamped at Ϫ60 mV. During whole cell recording the series resistance remained stable and only recordings with series resistance changes of Ͻ10% were included in the analysis. Only cells that showed significant recovery (to 60 -100%) from test agent application (except -agatoxin-TK, -conotoxin GVIA, mibefradil, and SNX-482 experiments) were included in the analysis.
Optic chiasm stimulation
EPSCs were evoked by electrical stimulation of the optic chiasm. A bipolar concentric tungsten electrode (FHC, Bowdoinham, ME) connected to a stimulus isolation unit (model SIU5B, Grass Medical Instruments, Quincy, MA) was placed in the optic chiasm and stimulated using a Grass S88 stimulator (Grass Medical Instruments). The pulse duration was 0.13-0.17 ms and the stimulation intensity was set 1.5-2 times higher than that needed to evoke a threshold response and usually varied between 8 and 40 V. EPSCs were elicited by electrical stimuli (square pulses) at 0.08 Hz.
Test agent application
All test agents were applied by perfusion of the recording chamber with artificial cerebrospinal fluid (ACSF) containing the final concentration of the compound. Chamber volume was about 400 l; a complete change of the external solution took Ͻ30 s at a flow rate of 1.5-2 ml/min. (Ϯ)Baclofen (GABA B receptor agonist, 0.03
, and DMSO were purchased from Sigma (St. Louis, MO). -Agatoxin TK (P/Q-type Ca 2ϩ channel blocker, 100 or 500 nM), -conotoxin GVIA (N-type Ca 2ϩ channel blocker 1 M), SNX-482 (R-type Ca 2ϩ channel blocker, 150 nM), tetrodotoxin (TTX, 750 nM), and tertiapin (a potent inhibitor of Kir3.1, Kir3.4, Kir1.1, and K ACh inwardly rectifying K ϩ channels, 10 or 100 nM) were purchased from Alomone Labs (Jerusalem, Israel). 4-Aminopyridine (4-AP, 1-5 mM) was purchased from Sigma (St. Louis, MO) and Tocris Cookson (Ellisville, MO). Appropriate stocks were made and diluted with ACSF just before application. -Agatoxin TK, -conotoxin GVIA, SNX-482, tertiapin, mibefradil, and baclofen, in experiments with the Ca 2ϩ channel blockers, were applied by perfusion through a micropipette with an internal diameter of 100 m. ACSF applied through micropipette contained the final concentration of test agent. The micropipette was placed close to the slice surface upstream of the SCN and the ACSF containing the toxins flowed out of the perfusion micropipette in the same direction to the flow of ACSF in the recording chamber (Fig. 1A) . The flow from micropipette completely covered the SCN. These Ca 2ϩ channel blockers were applied for 20 -40 min. (Fig. 1B) . In addition, the laminar flow (2 ml/min) of ACSF in the chamber was aimed away from the SCN to further reduce the possibility of depositing probe outside of the optic chiasm. Further, the likelihood of the probe getting into SCN neurons is low because rats of this age (Ͼ4 wk) have minimal uptake of AM probes into neurons while presynaptic terminals load well (Colwell 2000; Yuste 2000) . After injection, 2-3 h were allowed for probe transport into the RHT terminals. For experiments with Fluo-4 AM, a small amount of Texas Red-dextran (Molecular Probes) was added to the solution to help visualize the time course of probe loading. Fluorescent images were obtained with an upright microscope (DM LFS; Leica) with a water immersion objective (HCX AP L63X/0.9W U-V-I; Leica). To capture fast Ca 2ϩ transients, single-wavelength excitation was used. Excitation light (Fluo-4 480 nm; Fura-Red 440 and 488 nm) was from a monochronometer (Polychrome II or IV; Till Photonics, Martinsried, Germany), attenuated with a 0.6 or 1.3 neutral density filter (Chroma, Brattleboro, VT), passed through a band-pass filter (Fluo 4, HQ480/40x; Fura Red, D500/200, Chroma, Rockingham, VT) and reflected by a dichroic mirror (Fluo-4 Q505LP; Fura-Red 505dcxru; Chroma). The emitted light was filtered (Fluo-4, HQ535/50m; Fura-Red HQ645/75; Chroma). Optical recordings were made with either a cooled chargecoupled device (CCD, 16-bit level) camera (C6790 or ORCA ER; Hamamatsu Photonics, Hamamatsu, Japan) with binning Յ32x32 to minimize photo bleaching of the probe and maximize speed of data collection (3-49 ms/image), or a photodiode (Till Photonics S4753-02, Martinsried, Germany). Experiments using the CCD camera were controlled by digital imaging software (ARGUS HiSCA; Hamamatsu Photonics) and photodiode experiments by Pulse (HEKA). During the recording, slices were perfused in a 0.5 to 0.75 ml chamber at a temperature of 25°C. Electrical stimulation was by a concentric bipolar electrode placed in the optic chiasm about 200 m from the SCN, providing 200 s pulses at 0.08 Hz (PG4000 Digital Stimulator and SIU90; Neurodata Instrument, New York, NY). Optical data from photodiode and images from the CCD camera were converted to relative fluorescence intensity units (F), background was subtracted and corrected for signal loss over time, and the stimulation-induced presynaptic Ca 2ϩ transients were calculated using the fluorescence ratio ⌬F/Fo, where Fo is the baseline fluorescence before stimulation. In some experiments, the resting estimated Ca 2ϩ concentration (est [Ca 2ϩ ]) was determined by linearizing the Fura-Red AM response to Ca 2ϩ by using two excitation wavelengths, 440 and 488 nm, and the formula Est [Ca 2ϩ Grynkiewicz et al. 1985) , where Rmin, Rmax, and Sf/b (free/bound fluorescence at 488 nM) were determined in vitro using Fura-Red tetrapotassium salt with either 10 mM Ca 2ϩ for Rmax or 10 mM EGTA for Rmin; R is the ratio 440/488 nm corrected for background, and K d was taken to be 140 nM (Molecular Probes).
Optical measurements
] ϭ (R Ϫ Rmin)/(Rmax Ϫ R) ϫ Sf/b ϫ K d (
Math and statistical analysis
To calculate the inhibitory effect of baclofen on each Ca 2ϩ channel type we used the equation:
Ic is the percentage occlusion of baclofen effect by a Ca 2ϩ channel blocker, It is the percentage inhibition of the EPSC by the Ca 2ϩ channel blocker, Ib is the percentage inhibition of the EPSC induced by baclofen alone, and Itb is the percentage inhibition of EPSC produced by baclofen and the Ca 2ϩ channel blocker together. The peak amplitude, charge transfer, and 10 -90% rise time for EPSCs were averaged across neurons (five current traces were averaged for each neuron). EPSC amplitudes were measured as the difference between the peak EPSC current and the baseline current before the stimulus artifact. Data for each neuron represent an average of EPSC amplitudes from five sweeps over 1 min. Between neurons, these EPSC amplitudes were normalized and presented as the means Ϯ SE. Charge transfer represented the area enclosed by the EPSC and was analyzed during a 0.15-s period. To compare experimental protocols, amplitude, charge transfer, and rise time of EPSC were expressed as a percentage of control. Igor Pro (Version 5.0, Wave Metrics, Lake Oswego, OR) was used for curve fitting and data analysis. ANOVA, two-tail paired t-test, and unpaired t-test were performed using StatView 5.0.1 (SAS Institute, Cary, NC) or Excel 11.1.1 (Microsoft, Redmond, WA). A confidence level of 95% was used to determine statistical significance.
R E S U L T S
GABA B activation inhibits evoked EPSCs
Joint application of CNQX (10 M) and APV (50 M) with picrotoxin (50 M) was used to confirm that the currents activated in SCN neurons by stimulation of the optic chiasm were EPSCs mediated by glutamate release. CNQX (10 M) and APV (50 M) applied together significantly decreased the EPSC amplitude to 11.0 Ϯ 1.9 pA or 7.3 Ϯ 1.5% of control (control amplitude 156 Ϯ 16.8 pA, n ϭ 5, P Ͻ 0.0001; Fig. 2 ). This reduces the EPSC amplitude and confirms that stimulation of the optic chiasm evokes EPSCs mediated by glutamatereceptor activation.
Baclofen in the presence of picrotoxin (50 M) reversibly reduced the amplitude of EPSCs evoked by low-frequency (0.08-Hz) optic chiasm stimulation (Fig. 3, A and B) . The magnitude of the EPSC amplitude suppression was determined during the third through sixth minutes of baclofen application. Baclofen inhibited evoked EPSCs during both the subjective day and the subjective night in a concentration-dependent manner (0.03-30 M, Fig. 3C ). During the subjective day, baclofen (30 M) produced an 83.3 Ϯ 3.4% inhibition (n ϭ 4), which was not different from the inhibition observed during the subjective night (82.0 Ϯ 3.1%, n ϭ 6, P ϭ 0.80). The recordings were performed during the light phase from Zeitgeber Time (ZT) 4 to ZT11 (n ϭ 42 neurons) and during the dark phase from ZT12 to ZT21 (n ϭ 75 neurons), respectively. The IC 50 for baclofen was estimated to be 0.71 Ϯ 0.12 M during the subjective day and was not different from the IC 50 of 0.87 Ϯ 0.20 M (P ϭ 0.52) estimated during the subjective night. There was also no significant difference between the concentration-response curves determined during either the subjective day or night (F-test, P ϭ 0.80). These data indicate that GABA B receptors located on RHT terminals in the SCN inhibited glutamate release in a concentration-dependent manner and there was no diurnal variation in the presynaptic effect of GABA B receptors. The next studies were designed to determine whether GABA B receptors regulate the function of Ca 2ϩ or K ϩ channels in RHT terminals to modulate transmitter release.
Dependency of RHT synaptic transmission on extracellular Ca 2ϩ
Because the relationship between the presynaptic Ca 2ϩ concentration and glutamate release is unknown for RHT terminals, we examined the effects of changing the extracellular Ca 2ϩ concentration ([Ca 2ϩ ] e ) on the EPSC amplitude (Fig. 4 ). Decreasing the [Ca 2ϩ ] e from 2.4 to 1.2 mM significantly reduced the EPSC amplitude to 52.9 Ϯ 3.8% of control (98.1 Ϯ 5.0 pA, P Ͻ 0.0001, n ϭ 8), whereas a reduction to 0.6 mM further significantly reduced the EPSC amplitude to 20.6 Ϯ 3.5% of control (P Ͻ 0.0001, n ϭ 7, Fig. 4A ). The EPSC amplitude increased as [Ca 2ϩ ] e was raised from 0.6 to 2.4 mM, saturated when the extracellular [Ca 2ϩ ] e reached 2.4 mM, and remained stable through 3.5 mM [Ca 2ϩ ] e (Fig. 4B ).
Optical measurements of Ca 2ϩ in RHT terminals
GABA B -receptor activation could inhibit EPSCs by reducing the action potential-evoked increase in the presynaptic terminal Ca 2ϩ concentration required to trigger neurotransmitter release. Because of the nonlinearity of the relationship between Ca 2ϩ entry and transmitter release a relatively small decrease in the evoked presynaptic Ca 2ϩ transient might significantly reduce glutamate release. To test this hypothesis we measured the changes in RHT terminal Ca 2ϩ probe fluorescence after optic chiasm stimulation. We first confirmed that the optical measurements were from RHT terminal Ca 2ϩ and not from postsynaptic SCN neurons. Stimulation of the optic nerve produced a rapid increase in Ca 2ϩ probe fluorescence (transients) that was fully blocked by TTX (750 nM). Simultaneous application of CNQX (10 M), APV (50 M), and picrotoxin (50 M) did not change the RHT Ca 2ϩ transients, demonstrating that activation of postsynaptic AMPA, NMDA, or GABA A receptors did not confound the RHT-presynaptic Ca 2ϩ signal (Gompf et al. 2005) . Visual inspection of RHT terminals demonstrated probe fluorescence in terminal processes, but not in neuronal cell bodies (Gompf et al. 2005) . These data strongly support the conclusion that the Ca 2ϩ signal measured was presynaptic. Because presynaptic Ca 2ϩ transients might reach the micromolar range, it is possible that high-affinity Ca 2ϩ probes such as Fluo-4 or Fura-Red may become saturated. However, presynaptic Ca 2ϩ transients could be enhanced by 4-AP (1 mM) or by stimulation of the optic chiasm with pulses trains (Gompf et al. 2005) . Therefore changes in Ca 2ϩ probe fluorescence after a single stimulating pulse were within the linear range for the Ca 2ϩ concentration response of the probe. 
Relationship between presynaptic Ca 2ϩ entry and neurotransmitter release
To examine the relationship between the evoked EPSC amplitude and evoked presynaptic Ca 2ϩ transients, the extracellular Ca 2ϩ concentration ([Ca 2ϩ ] e ) was varied from 0.6 to 3.5 mM while electrically stimulating the optic chiasm. Concentration-response curves for the [Ca 2ϩ ] e and either EPSC amplitude or Ca 2ϩ transients demonstrated a saturating nonlinear relationship, with near saturation at about 2.4 mM [Ca 2ϩ ] e (Fig. 4B) . At 0.6 mM [Ca 2ϩ ] e , presynaptic Ca 2ϩ transient amplitudes in RHT terminals were reduced nearly 45% compared with a roughly 80% reduction of the EPSC amplitude (Fig. 4C) . This relationship implies that small changes in the amplitude of RHT terminal Ca 2ϩ transients equate to a much larger reduction in the EPSC amplitude.
Effect of baclofen on electrically induced RHT presynaptic Ca 2ϩ transients
Recordings of evoked Ca 2ϩ transients and resting Ca 2ϩ concentration were made using Fluo-4 AM; loaded RHT terminals with either photometry or Ca 2ϩ imaging techniques (six and eight experiments, respectively) showed similar results (Fig. 4D ). Experiments were performed in the presence of CNQX, APV, and picrotoxin. Baclofen (30 M) significantly attenuated (87.9 Ϯ 1.3% of control, P Ͻ 0.0001) evoked Ca 2ϩ transients and reduced the baseline Ca 2ϩ probe fluorescence 1.38 Ϯ 0.25% (P Ͻ 0.01, n ϭ 14). Because of the need for fast recordings, we used a single-wavelength Ca 2ϩ probe in the linear range to calculate ⌬F/Fo [i.e., (peak Ϫ baseline)/baseline]. This assumes that the baseline Ca 2ϩ concentration does not change with drug exposure. However, we have observed that baclofen lowers resting RHT terminal Ca 2ϩ (Fig. 4E) , and thus the evoked Ca 2ϩ transient could underestimate the ability of baclofen to lower presynaptic Ca 2ϩ . Because measured Ca 2ϩ transients reflect only activated terminals, whereas resting Ca 2ϩ reflects all the terminals, we were unable to combine the baclofen-induced reduction of resting Ca 2ϩ with the reduction in the Ca 2ϩ transient. Nonetheless, the reductions observed in EPSCs (roughly 80%) versus presynaptic calcium transients (nearly 12%) during baclofen application are consistent with the nonlinear relationship between Ca 2ϩ entry into presynaptic terminals and neurotransmitter release (Fig. 4C) .
Dependency of baclofen effect on extracellular Ca 2ϩ
Reducing [Ca 2ϩ ] e to 0.6 mM decreased the EPSC amplitude during baclofen (10 M) application to 2.1 Ϯ 0.2% of control, channels in mediating glutamate release from RHT terminals (P Ͻ 0.0001, n ϭ 40; Fig. 5, A and B) . Application of -agatoxin TK (500 nM) produced a 36.1 Ϯ 2.5% reduction (P Ͻ 0.0005, n ϭ 49; Fig. 5, C and D) , whereas a lower -agatoxin concentration (100 nM) produced a nonsignificant 20.3 Ϯ 4.8% reduction (P ϭ 0.5, n ϭ 4). SNX-482 (150 nM) induced a significant 17.5 Ϯ 3.0% reduction of the EPSC amplitude (P Ͻ 0.03, n ϭ 15; Fig. 5, E and F) , and nimodipine (10 M) a nonsignificant reduction of 5.6 Ϯ 2.7% (P ϭ 0.53, n ϭ 5; Fig. 5, G and H) . These data show that R-type but not L-type Ca 2ϩ channels participate in glutamate release from RHT terminals. Mibefradil (20 M) produced a significant 31.5 Ϯ 3.1% reduction of the EPSC amplitude (P Ͻ 0.0002, n ϭ 5; Fig. 5, I and J), indicating that T-type Ca 2ϩ channels contribute to the release of transmitter from RHT terminals.
The lack of a complete inhibition of the EPSCs by a single Ca 2ϩ channel blocker is consistent with a model in which multiple Ca 2ϩ channel types contribute to glutamate release from RHT terminals (Mintz et al. 1995; Regehr and Mintz 1994) . To test this possibility selective blockers were applied in combination (Fig. 6) . The order of -conotoxin and -agatoxin application was varied so that in half of the 14 experiments -agatoxin was applied first (Fig. 6, B and C) . Joint application of -conotoxin, -agatoxin, SNX-482, nimodipine, and mibefradil produced the largest reduction (87.1%) in the mean EPSC amplitude and the residual of 13% was completely blocked by Cd 2ϩ (100 M) (Fig. 8B ). In each case the observed inhibition produced by application of toxins in different combinations was less than that predicted by summing their individual inhibitory effects (Fig.  6A ). These data indicate that activation of high-voltageactivated N-, P/Q-, R-type and low-voltage-activated Ttype Ca 2ϩ channels demonstrate cooperatively in regulation of glutamate release from RHT terminals. The small difference between the observed and predicted inhibition produced by SNX-482 with either -conotoxin or -agatoxin suggests a minimal overlap in effect of these blockers on glutamate release. In contrast, overlap of -conotoxin and -agatoxin actions was greater (Յ33%).
Identification of the presynaptic Ca 2ϩ channels inhibited by GABA B -receptor activation
Experiments were performed to determine whether GABA Breceptor activation decreased RHT transmission by inhibiting voltage-dependent Ca 2ϩ channels. The EPSC amplitudes recorded when baclofen was applied on a background of prior Baclofen (0.3 and 10 M) evoked a significant reduction of the EPSC amplitude (26.6 or 73.7% respectively; Fig. 7, A and  B) . The maximal inhibitory effect occurred 3.3 Ϯ 0.3 min (n ϭ 13) after beginning the baclofen application. After washout, the EPSC amplitude recovered to 70 -100% of control for 25-40 min. To determine whether there was an interaction between GABA B receptors and N-, P/Q-, T-, R-, or L-type Ca 2ϩ channels, various Ca 2ϩ channel blockers were applied alone or together with baclofen (0.3 or 10 M) (Fig. 7) . The -conotoxin (1 M) plus baclofen (0.3 or 10 M) effect (73.7 Ϯ 6.0%, n ϭ 12 or 92.1 Ϯ 1.7%, n ϭ 7 reduction, respectively) was significantly greater than the effect of -conotoxin alone (Fig. 7, C and D) . From experiments combining -conotoxin with baclofen at low concentration (0.3 M) and a nearly maximal concentration (10 M), we calculate 72.2 and 48.6% (respectively) of baclofen's effect was mediated by inhibition of N-type Ca 2ϩ channels (Fig. 8A ) (see Math and statistical analysis). -Agatoxin (500 nM) and baclofen (0.3 or 10 M) were applied together to study a possible interaction between GABA B receptors and P/Q-type channels (Fig. 7, E and F) , and reduced the EPSC amplitude 62.2 Ϯ 5.5% (n ϭ 12) or 96.1 Ϯ 0.5% (n ϭ 4), respectively. These data indicate that P/Q-type Ca 2ϩ channels contribute 15.4% at low and 6.8% at high baclofen concentrations to baclofen's inhibition of evoked EPSCs (Fig. 8A) .
GABA B -receptor inhibition of R-type Ca 2ϩ channels was studied by applying SNX-482 (150 nM) together with baclofen (0.3 or 10 M). This resulted in a 45.6 Ϯ 6.1% (n ϭ 6) or 92.9 Ϯ 1.7% (n ϭ 5) reduction, respectively (Fig. 7, G and H) . Because SNX-482 did not significantly reduce baclofen's inhibition from baclofen alone, we conclude that baclofen does not modulate R-type Ca 2ϩ channels at either low or high concentrations (1.1 and 1.0%, respectively; Fig. 8A ).
GABA B -receptor-mediated inhibition of T-type Ca 2ϩ channels was studied by applying mibefradil (20 M) together with baclofen (0.3 or 10 M). Mibefradil plus baclofen produced a 50.8 Ϯ 5.3% (n ϭ 8) or 82.4 Ϯ 6.2% (n ϭ 6) reduction, respectively, for 0.3 and 10 M baclofen (Fig. 7, I and J). The component of baclofen's effect occluded by mibefradil was estimated to be 51.9 and 23.9% in low and high concentrations of baclofen, respectively. Thus mibefradil has a greater effect at lower than higher baclofen concentrations, and indicates a strong effect of baclofen on T-type Ca 2ϩ channels. In contrast, evoked EPSCs inhibited by application of baclofen (10 M) together with nimodipine (10 M) were not significantly different from baclofen alone (Fig. 7K) .
Joint application of -agatoxin, -conotoxin, SNX-482, nimodipine, mibefradil, and baclofen (10 M) inhibited EPSCs 97.5 Ϯ 1.9% compared with 81.8 Ϯ 1.1% inhibition evoked by these toxins alone (n ϭ 3). Thus the blocker cocktail does not completely inhibit the evoked EPSCs. Because baclofen (10 M) applied with this cocktail almost completely blocked the remaining EPSCs, we calculated that the residual inhibitory baclofen effect was 15.7% (Fig. 8B) .
Finally, because the application of Ca 2ϩ channel blockers alone or jointly cannot completely block glutamate release, it suggests the existence of Ca 2ϩ currents resistant to the applied blockers. These remaining Ca 2ϩ currents were almost completely inhibited by the addition of baclofen (10 M). Cd 2ϩ (100 M) in the same experiments also completely blocked the EPSC (Fig. 8B) . channel blockers were applied together and the EPSC amplitude recorded. Magnitude of the reduction of the EPSC amplitude produced by the combination of blockers was compared with the calculated sum of their individual effects. Observed inhibition was generally less than that predicted by summing the effects of the individual blockers. Error bars represent SE; NS, nonsignificant, **P Ͻ 0.01, ***P Ͻ 0.001. For blockers applied together: n ϭ 9 (agatoxin, SNX), n ϭ 3 (conotoxin, SNX), n ϭ 14 (agatoxin, conotoxin), n ϭ 10 (agatoxin, conotoxin, nimodipine), n ϭ 14 (agatoxin, conotoxin, nimodipine, SNX), n ϭ 5 (agatoxin, conotoxin, nimodipine, SNX, mibefradil). B and C: changing the order of -conotoxin and -agatoxin application had no effect on the magnitude of EPSC inhibition.
Baclofen does not activate presynaptic K
(Kir3) (Andrade et al. 1986; Sodickson and Bean 1996) . We designed experiments to determine whether the GABA B -receptor-mediated inhibition of glutamate release at RHT terminals could be attributable, in part, to an activation of presynaptic Kir3 channels. To block Kir3 channels we used a peptide toxin tertiapin, a potent blocker of Kir3.1, Kir3.4, Kir1.1, and K ACh inwardly rectifying K ϩ channels and Ba 2ϩ (BaCl 2 ). Tertiapin (10 nM) application produced a small nonsignificant decrease in the EPSC amplitude to 95.9 Ϯ 7.9% of control (control 70.4 Ϯ 10.0 pA) and did not change the charge . E and F: baclofen and agatoxin (500 nM) (E, n ϭ 12; F, n ϭ 4). G and H: baclofen and SNX-482 (150 nM) (G, n ϭ 6; H, n ϭ 5). I and J: baclofen and mibefradil (20 M) (I, n ϭ 8; J, n ϭ 6). K: baclofen and nimodipine (10 M) (n ϭ 5). Current traces are individual EPSCs recorded in control, channel blocker, and channel blocker plus baclofen conditions. NS, nonsignificant; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. transfer (n ϭ 7; Fig. 9, A, E, and F) . Similarly, the EPSC amplitude was not significantly reduced (92.4 Ϯ 5.7% of control, P ϭ 0.32, n ϭ 11) in the presence of a higher tertiapin (100 nM) concentration. Application of baclofen (10 M) with tertiapin (10 nM) reduced the EPSC amplitude to 23.7 Ϯ 6.7% and the charge transfer (n ϭ 7; Fig. 9, A, E, and F) , values that were not significantly different from baclofen alone (Fig. 9, E  and F) .
Application of BaCl 2 (1 mM) increased the EPSC amplitude to 131.4 Ϯ 11.1% of control (control 84.8 Ϯ 22.2 pA) and significantly enhanced the charge transfer (n ϭ 5; Fig. 9 , B, E, and F), presumably by depolarizing the nerve terminals (De Jeu et al. 2002) . Baclofen added together with BaCl 2 reduced the EPSC amplitude (28.5%) and the charge transfer, values that were not significantly different (P ϭ 0.72, n ϭ 5) from the effect of baclofen alone (Fig. 9, B, E, and F) . Baclofen blocked all additional current that was evoked by BaCl 2 application. Baclofen application in the presence of tertiapin or BaCl 2 did not reduce the EPSC amplitude and the charge transfer to a greater extent than the reduction evoked by baclofen alone.
These studies with tertiapin and Ba 2ϩ suggest that baclofen was not activating Kir3 channels because blocking K ϩ channels did not alter baclofen's inhibition of glutamate release.
Application of 4-AP (5 mM) significantly increased the EPSC amplitude to 153 Ϯ 14.6% of control (control 109.0 Ϯ 9.4 pA), the charge transfer (n ϭ 9; Fig. 9, C-F) , and the amplitude of the evoked Ca 2ϩ transients (Gompf et al. 2005) . Baclofen added together with 4-AP reduced the EPSC amplitude to 75.8 Ϯ 9.0%, a value that was significantly different from the effect of baclofen alone (n ϭ 9; Fig. 9, C-E) . After baclofen application the charge transfer remained 31% larger than in control (131.2 Ϯ 24.2% of control) and more than fourfold larger than baclofen alone (30.0 Ϯ 3.3% of control; Fig. 9F ). These data show that application of 4-AP significantly decreases the magnitude of the baclofen-induced inhibition. After joint application of 4-AP and baclofen (10 M), the EPSC amplitude remained larger than the control EPSC amplitude in two neurons (Fig. 9D) .
4-AP and Ba 2ϩ increased the charge transfer (225.0 Ϯ 24.1 and 144.1 Ϯ 18.0% of control, respectively). Charge transfer (131.2 Ϯ 24.2% of control, P Ͻ 0.006) remained significantly higher than in control when baclofen was applied together with 4-AP. Ba 2ϩ or tertiapin together with baclofen induced a charge transfer (29.9 Ϯ 9.1 and 32.5 Ϯ 6.1% of control, respectively) that was not significantly different (P ϭ 0.99 and P ϭ 0.72) from baclofen alone (30.0 Ϯ 3.2%).
Unlike Ba 2ϩ , 4-AP increased the 10 -90% rise time of the EPSC [108.8 Ϯ 13.3% (P ϭ 0.96, n ϭ 5) and 174.4 Ϯ 26.3% of control, respectively]. Application of baclofen (10 M) with BaCl 2 or with 4-AP increased the EPSC rise time in both cases (129.6 Ϯ 35.8 and 252.3 Ϯ 34.8%, respectively). These data demonstrate that the baclofen effect on the rise time in the presence of Ba 2ϩ was not significantly different from that of baclofen alone (135.9 Ϯ 20.7%, P ϭ 0.12). Thus Ba 2ϩ , unlike 4-AP, does not alter the EPSC rise time when applied alone or together with baclofen. Thus 4-AP and Ba 2ϩ significantly increased the EPSC amplitude and charge transfer. Ba 2ϩ , unlike 4-AP, did not change the EPSC rise time in either the presence or the absence of baclofen. The charge transfer remained significantly larger than control when baclofen was applied together with 4-AP, in contrast to Ba 2ϩ or tertiapin, which did not alter baclofen's effect.
Effect of increasing the extracellular K ϩ on EPSC inhibition evoked by baclofen
To evaluate whether changes in the presynaptic membrane potential could alter the effect of baclofen on glutamate release, we varied the extracellular KCl concentration from 2.5 to 25 mM, and correspondingly decreased the NaCl concentration, to balance osmolality. Increasing the extracellular K ϩ ([K ϩ ] e ) depolarizes presynaptic terminals (Hoss and Labkovsky 1986) . As expected, raising the [K ϩ ] e resulted in an exponential increase in resting presynaptic Ca 2ϩ concentration, and a biphasic concentration-response relationship for both evoked EPSCs and presynaptic Ca 2ϩ transient amplitudes (Fig.  10D) . The EPSC was completely blocked by [K ϩ ] e Ͼ20 mM (Fig. 10A) . These data suggest that strong depolarization of optic nerve terminals can completely block EPSCs by blocking action potential propagation. In contrast, raising [K ϩ ] e to 7-12 mM increased the EPSC amplitude (Fig. 10, B, C, and D) to (Fig. 10D ). Thus the depolarization of RHT terminals evoked by increasing [K ϩ ] e does not significantly alter baclofen's inhibitory effect on EPSCs.
D I S C U S S I O N
Environmental light information is conveyed to the SCN from RGCs that project glutamatergic fibers by the RHT terminating on SCN neurons (Berson et al. 2002; Card and Moore 1991; Castel et al. 1993; Liou et al. 1986; Moore et al. 1995) . The majority of RGCs that project to the SCN express the photopigment melanopsin (Gooley et al. 2003; Morin et al. 2003; Sollars et al. 2003) . Synaptic transmission at RHT-SCN neuron synapses and light's effect on circadian clock timing can be modulated by activation of presynaptic GABA B receptors reducing glutamate release from RHT terminals (Colwell et al. 1993 . Each point represents the means Ϯ SE of the amplitudes of 5 EPSCs recorded during a 1-min period. E: summary of the effect of tertiapin (10 nM), BaCl 2 , and 4-AP alone and applied together with baclofen (10 M) on the EPSC amplitude. F: effect of each K ϩ channel blocker applied alone and together with baclofen (10 M) on the charge transfer (EPSC). Quantity of neurons: 4-AP (n ϭ 9), Ba 2ϩ (n ϭ 5), tertiapin (n ϭ 7), baclofen alone (n ϭ 13). NS, nonsignificant; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. modulation of RHT transmission has significant effects on light entrainment of the circadian clock. Activation of either GABA B or 5-HT 1B receptors reduces the magnitude of lightinduced phase shifts (Gillespie et al. 1997 (Gillespie et al. , 1999 Pickard and Rea 1997; Pickard et al. 1999) . The GABA B and 5-HT systems may overlap in their regulation of photic input to the circadian system. Presynaptic 5-HT 1B receptors inhibit GABA release in the SCN that may contribute to the tonic GABA B -receptormediated inhibition (Bramley et al. 2005; Gannon et al. 1995; Sollars et al. 2006) . 5-HT 1B -knockout mice have smaller lightinduced phase shifts than would be predicted, possibly arising from disinhibition of GABA B signaling by removal of 5-HT inhibition of GABA release (Sollars et al. 2006) . Mice with the 5-HT 1B receptors knocked out have a delayed phase angle of entrainment (Sollars et al. 2006) . Interestingly a similar delayed phase angle of entrainment is present in humans with seasonal affective mood disorders (Lewy et al. 1987) .
We have shown that GABA B -receptor activation reduces transmission at RHT synapses by inhibiting primarily N-, T-, and P/Q-type voltage-gated Ca 2ϩ channels that are required for glutamate release. R-type voltage-gated Ca 2ϩ channels also contribute to glutamate release but are not affected by activation of presynaptic GABA B receptors. L-type Ca 2ϩ channels and Kir3 channels contribute neither to glutamate release from RHT terminals nor to GABA B presynaptic inhibition. The magnitude of the effect on RHT synaptic transmission was dependent on the GABA B agonist concentration but was not dependent on the circadian time.
Role of voltage-dependent Ca 2ϩ channels in glutamate release from RHT terminals
Selective Ca 2ϩ channel blockers were used to determine the contribution of specific types of Ca 2ϩ channels to RHT transmission. These toxins do not have postsynaptic effects on glutamatergic responses nor do they alter the number of stimulated afferents (Luebke et al. 1993; Mintz et al. 1995) . We have shown that N-, P/Q-, T-, and R-type, but not L-type, Ca 2ϩ channels contribute the Ca 2ϩ required for glutamate release from RHT terminals. During low-frequency stimulation (0.08 Hz) the EPSC amplitudes were reduced nearly 70% by N-type channel inhibition, nearly 30% by either P/Q-type or T-type channel inhibition, and nearly 20% by R-type Ca 2ϩ channel inhibition. Blocking L-type channels with nimodipine had no significant effects on RHT synaptic transmission. -Agatoxin produced almost twice the reduction of the evoked EPSC at 500 than at 100 nM, suggesting that Q-type (IC 50 ϭ 90 nM) channels have the same importance in regulating release as P-type channels (IC 50 ϭ 1-3 nM).
To study which types of Ca 2ϩ channels are involved we used specific blockers (see above). However, mibefradil is not completely selective for T-type Ca 2ϩ channels. Our observations on mibefradil effects on EPSCs can be explained in two different ways. First, mibefradil specifically blocks low-voltage-activated T-type Ca 2ϩ channels (Lacinova 2004 mibefradil blocks several Ca 2ϩ channel types to reduce the evoked EPSC amplitude (Bezprozvanny and Tsien 1995; Liu et al. 1999; Viana et al. 1997) . Our data were consistent with the first possibility because in the presence of N-, P/Q-, R-, and L-type Ca 2ϩ channel blockers mibefradil blocked an additional roughly 10% of the EPSC amplitude. This interpretation must be made with caution because we cannot exclude the blocking effect of mibefradil on Na ϩ and K ϩ channels (Liu et al. 1999 ). Multiple types of Ca 2ϩ channels with overlapping functions mediate glutamate release at RHT terminals. Application of any two toxins reduced the EPSC amplitude less than would be expected from the sum of their individual ability to reduce EPSC amplitude (Fig. 6) . The sum of the inhibition produced individually by N-, P/Q-, and T-type Ca 2ϩ channels blockers was greater than inhibition produced by their joint application. For example, the overlap between the effect of N-and P/Qtype Ca 2ϩ channels was estimated to be 33%, but there was no overlap with R-type Ca 2ϩ channels. These data are consistent with the activity of multiple Ca 2ϩ channels overlapping to initiate transmitter release. Previous studies have similarly demonstrated that blocking synaptic currents by selective antagonists of N-and P/Q currents sum to Ͼ100% (Mintz et al. 1995; Reid et al. 1998; Wheeler et al. 1996) . A model was proposed in which "multiple types of Ca 2ϩ channels exert synergistic control over individual release sites, and that the domains of several Ca 2ϩ channels must overlap at each release site" (Mintz et al. 1995) . The regulation of glutamate release from RHT terminals by multiple types of voltage-dependent Ca 2ϩ channels is consistent with such a model. Joint application of -conotoxin GVIA, -agatoxin TK, mibefradil, SNX-482, and nimodipine in saturating concentrations evoked an 87% decrease of the control EPSC amplitude and should completely block N-, P/Q-, T-, R-, and L-type Ca 2ϩ channels. The component of the EPSC (13%) that was not inhibited by these blockers was inhibited by Cd 2ϩ and might reflect the contribution of SNX-482-resistant R-type Ca 2ϩ channels (Tottene et al. 2000) . In axons of the rat optic nerve and RGCs nearly 40 -60% of the evoked Ca 2ϩ influx accounted for N-type Ca 2ϩ channels, whereas P/Q-type Ca 2ϩ channels make little, if any, contribution (Guenther et al. 1994; Sun and Chiu 1999) . In RGCs, L-type Ca 2ϩ channels mediate 25% of the Ca 2ϩ current (Guenther et al. 1994) . Immunocytochemical studies confirmed the presence of L-type Ca 2ϩ channels in axons of adult rat optic nerve, although they contribute little to evoked Ca 2ϩ influx (Brown et al. 2001; Sun and Chiu 1999) . The insignificant contribution of L-type channels in transmitter release can be explained by localization of L-type channels far from release sites at these axonal terminals.
During electrophysiological recordings, we noted that there was a large variation of the magnitude of toxin effects (Fig. 5) . For example, -conotoxin produced as much as 100% inhibition and as little as 20% inhibition. One explanation is that delivery of the toxin varied across the experiments but this is unlikely because baclofen application from the same micropipette showed a consistent effect. An alternate explanation is that different RHT fibers have different complements of Ca 2ϩ channels (Reid et al. 2003) . Those that rely on N-type channels for glutamate release would be more sensitive to block by -conotoxin than those that rely more on P/Q-or R-type channels. Our data suggest that the different types of Ca 2ϩ channels can vary considerably in different RHT terminals (Fig. 5) .
Presynaptic effect of baclofen on voltage-dependent Ca 2ϩ channels
GABA B -receptor activation reduces the release of glutamate from axon terminals of the RHT (Jiang et al. 1995) . The magnitude of the effect is dependent on the GABA B -agonist concentration but is not dependent on the circadian time (Fig.  3) . The IC 50 for baclofen-evoked inhibition during the subjective day was not significantly different from that during the subjective night (IC 50 Х 1 M) and was similar to those measured in the rat optic nerve and in the calyx of Held (Sun and Chiu 1999; Takahashi et al. 1998) . Further the concentration-response curves recorded during the day or night were not significantly different (Fig. 3) .
Activation of GABA B receptors inhibited the release of glutamate from RHT terminals as measured by a reduction in the EPSC amplitude. Blocking specific types of voltage-dependent Ca 2ϩ channels attenuated the magnitude of the GABA Bagonist-induced reduction. The GABA B -receptor regulation is not uniform across all types of Ca 2ϩ channels. We estimate that depending on the baclofen concentration (0.3-10 M) that was applied, nearly 49 -72% of the presynaptic inhibition produced by GABA B -receptor activation was mediated by block of N-type Ca 2ϩ channels, nearly 24 -52% mediated by block T-type Ca 2ϩ channels, and nearly 7-15% mediated by block of P/Q-type Ca 2ϩ channels. The effect of GABA Breceptor activation was not mediated by R-type (nearly 1% inhibition) or L-type Ca 2ϩ channels. Similarly, baclofen-induced inhibition was occluded by block of N-type Ca 2ϩ channels in axons of neonatal rat optic nerve (Sun and Chiu 1999) . Recently G-proteins were shown to bind more strongly to Cav2.2 (␣ 1B, N-type) than Cav2.1 (␣ 1A, P/Q-type) Ca 2ϩ channels (Agler et al. 2003) . This may explain why baclofen inhibits N-type more than P/Q-type Ca 2ϩ channels. These effects of baclofen are mediated by G␤␥ that directly inhibits Ca 2ϩ channels, putting them into a reluctant state (Kajikawa et al. 2001; Zamponi and Snutch 1998) .
Effect of baclofen on resting and evoked presynaptic Ca 2 transients
The relationship between evoked EPSC amplitude and [Ca 2ϩ ] e was sigmoidal, whereas the relationship between presynaptic Ca 2ϩ transients and [Ca 2ϩ ] e approximated a hyperbolic response (Mintz et al. 1995) . Reduction of Ca 2ϩ influx in presynaptic terminals by baclofen has previously been reported in different brain structures (Barnes-Davies and Forsythe 1995; Dittman and Regehr 1996; Isaacson 1998; Wu and Saggau 1997) . A similar effect of baclofen on presynaptic Ca 2ϩ influx and EPSC amplitude (correspondingly about 50 and 90% reduction of initial value) was shown in presynaptic terminals of the calyx of Held (Sakaba and Neher 2003 (Dittman and Regehr 1996; Wu and Saggau 1997) . These studies differed by examining different regions of the brain and by using different Ca 2ϩ indicators. Overall, our data are consistent with a nonlinear relationship between presynaptic RHT Ca 2ϩ concentration and glutamate release, such that GABA B receptor activation producing a small reduction in the evoked presynaptic Ca 2ϩ transient can have a large effect on inhibiting glutamate release.
Role of K ϩ channels in RHT transmission and in modulation of baclofen effect
Tertiapin and BaCl 2 were used to study whether the GABA B agonist baclofen activates Kir3 channels on RHT presynaptic terminals. Tertiapin did not change the EPSC amplitude or charge transfer. Neither tertiapin nor Ba 2ϩ blocked baclofeninduced presynaptic inhibition in RHT synapses. These data are in agreement with studies showing that Ba 2ϩ does not block presynaptic inhibition induced by baclofen in excitatory (glutamatergic) synapses (Cui et al. 2000; Takahashi et al. 1998; Thompson and Gahwiler 1992) . Similarly, baclofen does not directly increase a K ϩ conductance in the optic nerve (Sun and Chiu 1999) . Moreover, G-protein-activated Kir current can be detected in the presynaptic terminal but it cannot be activated by baclofen (Takahashi et al. 1998 ). Baclofen-induced inhibition does not require activation of Kir3 channels on excitatory terminals because the presynaptic effect of GABA B receptors was unaltered in mutant mice lacking the GIRK2 gene (Lüscher et al. 1997 ). Thus our data show that baclofen does not activate Kir3 channels in RHT axon terminals, unlike its effect on RGCs (Chen et al. 2004 ).
More than 60% of outward K ϩ currents in presynaptic terminals are sensitive to 4-AP and are very important for regulation of synaptic transmission (Forsythe 1994; Reiff and Guenther 1999) . 4-AP potentiates EPSCs by broadening presynaptic action potentials and slowing action potential repolarization (Ishikawa et al. 2003; Sun and Chiu 1999) . 4-AP application onto the optic nerve induced a delayed inward Ca 2ϩ current that forms a second "hump" on the action potential (Sun and Chiu 1999) . The "hump" was blocked partially by baclofen, although the Ca 2ϩ transient remained unaffected (Sun and Chiu 1999) . These data are intriguing because 4-AP application increased Ca 2ϩ influx and the EPSC amplitude and dramatically decreased the baclofen-induced inhibition in RHT terminals (Fig. 9D) (Gompf et al. 2005; Liang et al. 2002) . The 4-AP effect was so strong that after baclofen application charge transfer remained 31% larger than in control.
The mechanism of disinhibition of baclofen's presynaptic effect by 4-AP was not clear. One explanation was that baclofen's effect could be altered by depolarization of presynaptic terminal. It is known that depolarization of the nerve terminal relieves baclofen-and G␤␥-induced inhibition of presynaptic Ca 2ϩ channels (Isaacson 1998; Kajikawa et al. 2001 ). Another explanation is that 4-AP blocks voltage activated K ϩ channels (Kv) Kv3.1/Kv2.1 and enhances Na ϩ and Ca 2ϩ influx in presynaptic terminals (Ishikawa et al. 2003; Kirsch and Drewe 1993) . Elevation of axonal [Na ϩ ] i also induces Ca 2ϩ influx into the axon (Verbny et al. 2002) . Increasing the Ca 2ϩ influx could partially relieve baclofeninduced inhibition (Fig. 4B) . At the same time it is unclear why depolarization of RHT terminals evoked by Ba 2ϩ application or by high [K ϩ ] e did not reduce the baclofen effect. Thus we can state only that 4-AP-sensitive K ϩ currents were important for baclofen-induced inhibition because baclofen significantly increased the transient outward K ϩ current (I A ) and shifts the activation of I A to more positive potentials (Saint et al. 1990; Takeda et al. 2004) . The effects of GABA B -receptor activation on I A could be similar to other G-protein-coupled receptors (cannabinoid, opioidergic, and serotonergic) whose presynaptic inhibition used an opening 4-AP-sensitive K ϩ channel by G-proteins (Childers et al. 1993; Kishimoto et al. 2001) . We conclude that activation of GABA B receptors inhibits voltagedependent Ca 2ϩ channels but does not activate Kir3 channels in RHT presynaptic terminals and GABA B inhibitory effect could be reduced by block of 4-AP-sensitive K ϩ currents.
Comparing GABA B presynaptic inhibition of evoked EPSCs and IPSCs in the SCN
It is important to note similarities and differences in GABA B presynaptic inhibition of EPSCs and inhibitory postsynaptic currents (IPSCs) in the SCN. Presynaptic GABA B -receptor activation inhibits IPSCs recorded from single autaptic SCN cells (Chen and Van den Pol 1998) . Comparison with our data shows that baclofen dose-dependently inhibits both EPSCs and IPSCs. Activation of presynaptic GABA B receptors suppresses transmitter release through G-protein-coupled inhibition of Nand P/Q-type Ca 2ϩ channels and have no effect on L-type Ca 2ϩ channels when EPSCs and IPSCs were studied (Chen and Van den Pol 1998). There is no evidence for a contribution of Kir3 channels in the presynaptic baclofen effect on IPSC (Chen and Van den Pol 1998) . However, it has been shown that there are differences in the effect of baclofen on EPSCs and IPSCs. Baclofen presynaptically inhibits IPSCs by activation of GABA B autoreceptors, with a larger effect on P/Q-and lesser effect on N-type Ca 2ϩ channels (Chen and Van den Pol 1998) . This observation is different from the baclofen effect on EPSCs in brain slices of adult rats, where inhibition of N-and T-type Ca 2ϩ channels was larger than that of P/Q-type Ca 2ϩ channels. Our data demonstrate that baclofen has a strong inhibitory effect on presynaptic T-type Ca 2ϩ channels and does not regulate glutamate release by inhibiting R-type Ca 2ϩ channels. It is important to be cautious when comparing the ratio of N-type and P/Q-type Ca 2ϩ channels in GABAergic axonal terminals of SCN cells and in glutamatergic RHT terminals because the experimental models were different (cell culture from neonatal pups and brain slices from adult rats). In shortand long-term culture models, different types of Ca 2ϩ channels begin to participate in transmitter release at different times during synapse development and maturation (Scholz and Miller 1995) . Also, Ca 2ϩ channel expression might be different in adult and young animals (Forti et al. 2000) . Additional studies of the effect of Ca 2ϩ channel blockers on IPSCs in adult animals are necessary to answer this question.
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